Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Benefits of an Attitude of Gratitude
December 21, 2009
- Takara Bio Obtains Patent on Expansion Culture of Lymphocytes
December 21, 2009
- DPP-4/GLP-1 Drugs Need Further Assessment in Actual Medical Practice: Prof. Niki
December 21, 2009
- CMIC Acquires DS Propharma's Shizuoka Plant
December 21, 2009
- Taxotere to Become New Treatment Option for Prostate Cancer: Prof. Akaza
December 21, 2009
- Cut and Thrust About 2% Price Cut for Long-Listed Drugs at Chuikyo
December 21, 2009
- Symbicort Renovates Asthma Treatment in Japan: Prof. Adachi
December 21, 2009
- Punishment Proposed by Korosho for Firms That Fail to Develop Requested Drugs
December 21, 2009
- OAB Still Undertreated: Prof. Takahashi
December 21, 2009
- Proposed FY2010 NHI Drug Pricing System Reform (Draft)
December 21, 2009
- Use of Biologics Recommended at Early Stage for RA
December 21, 2009
- Korosho Aims at First Net Increase in Medical Fees in 10 Years
December 21, 2009
- JCR to Verify Acceptability of New ACR/EULAR RA Criteria in Japan
December 21, 2009
- 2-Year Extension OK'd for R&D Tax Breaks for Both Increased and High-Level Investment
December 14, 2009
- Merck Serono Aims to Launch Cancer Vaccine by 2015
December 14, 2009
- Takara Bio Begins PI Trial for Gene Therapy for Relapsed Leukemia
December 14, 2009
- Industry-Proposed Price Maintenance System Meets No Strong Opposition at Chuikyo
December 14, 2009
- Crestor Reduces CV Events Risk in Women by 46%
December 14, 2009
- A Ray of Light for Industry's Proposal?
December 14, 2009
- Actemra Improves sJIA in Children: Roche, Chugai
December 14, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…